In:
Cancer, Wiley, Vol. 127, No. 22 ( 2021-11-15), p. 4161-4170
Abstract:
This is the first prospective trial to evaluate the efficacy and safety of doxorubicin‐based concurrent chemotherapy with intensity‐modulated radiation therapy (CC‐IMRT) in patients with locally advanced nonanaplastic differentiated thyroid cancer. CC‐IMRT achieves excellent locoregional disease control and has an acceptable toxicity profile; this suggests that doxorubicin‐based CC‐IMRT should be considered as a treatment for gross residual or unresectable nonanaplastic differentiated thyroid cancer.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
DOI:
10.1002/cncr.v127.22
Language:
English
Publisher:
Wiley
Publication Date:
2021
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
2599218-1
detail.hit.zdb_id:
2594979-2
detail.hit.zdb_id:
1429-1
